Independent program administrator issues annual report

Major League Baseball and the Major League Baseball Players Association today released the annual public report from the Joint Drug Prevention and Treatment Program's Independent Program Administrator. The Joint Drug Prevention and Treatment Program calls for a public report to be issued by December 1st of each year.

The accompanying report from the Independent Program Administrator, Jeffrey M. Anderson, M.D., covers the period from the beginning of the 2014-2015 off-season through the end of Major League Baseball's 2015 Postseason. This year's report also includes the total number of in-season tests and off-season tests conducted during the previous five years.

2015 Public Report of Major League Baseball's Joint Drug Prevention and Treatment Program

This report covers the time from the beginning of the 2014‐2015 Major League Baseball off‐season to the end of the 2015 Major League Baseball post‐season (the "2015 Reporting Period"). Additionally, this report also includes the total number of in‐season tests and off‐season tests conducted during the previous five years. As per agreement between the Office of the Commissioner of Baseball and the Major League Baseball Players Association, this report is specific to players who compose 40‐man rosters for Major League Baseball Clubs.

1) The total number of drug tests that were conducted during the 2015 Reporting Period was 8,158 tests. Of this total number, the number of urine specimens that were collected and analyzed for Performance Enhancing Substances, Stimulants and DHEA was 6,536.

The number of blood specimens that were collected and analyzed for the presence of human growth hormone (hGH) was 1,622.

2) Ten (10) adverse analytical findings were reported by the testing laboratory that resulted in discipline. Seven (7) were for Performance Enhancing Substances, two (2) were for Stimulants, and one (1) was for DHEA. The substances involved in these adverse analytical findings were as follows:

Performance Enhancing Substances (7)

Dehydrochlormethyltestosterone (DHCMT): 1
Ipamorelin: 1
Stanozolol: 4
Stanozolol and Boldenone: 1

Stimulants (2)

Adderall: 1
Phentermine: 1

DHEA (1)

3) 113 Therapeutic Use Exemptions were granted. The categories of medications were as follows:

Attention Deficit Disorder: 111
Gynecomastia: 1
Olecranon Stress Fracture/Hypercalciuria: 1 

4) The total number of drug tests that were conducted for the presence of Performance Enhancing Substances, Stimulants and/or DHEA during the previous five (5) years was 30,482 tests. Of this total number, the number of in‐season tests that were conducted was 29,101.

The number of off‐season tests that were conducted was 1,381. The year‐by‐year breakdown of the testing is noted below:

YEAR

TOTAL TESTS

IN‐SEASON TESTS

OFF‐SEASON TESTS

2011

3,868

3,723

145

2012

5,136

5,008

128

2013

5,391

5,118

273

2014

7,929

7,622

307

2015

8,158

7,630

528

TOTAL

30,482

29,101

1,381

Respectfully submitted,

Jeffrey M. Anderson, MD
Independent Program Administrator
Major League Baseball's Joint Drug Prevention and Treatment Program